Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-04
2009-10-06
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
07598273
ABSTRACT:
Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.
REFERENCES:
patent: 4628098 (1986-12-01), Nohara
patent: 4758579 (1988-07-01), Kohl
patent: 5013743 (1991-05-01), Iwahi
patent: 5026560 (1991-06-01), Makino
patent: 5045321 (1991-09-01), Makino
patent: 5093132 (1992-03-01), Makino
patent: 5433959 (1995-07-01), Makino
patent: 5464632 (1995-11-01), Cousin et al.
patent: 5690960 (1997-11-01), Bengtsson et al.
patent: 5714504 (1998-02-01), Lindberg et al.
patent: 5840737 (1998-11-01), Phillips
patent: 5877192 (1999-03-01), Lindberg
patent: 5900424 (1999-05-01), Kallstrum et al.
patent: 5997903 (1999-12-01), Dietrich
patent: 6123962 (2000-09-01), Makino
patent: 6143771 (2000-11-01), Lindberg
patent: 6147103 (2000-11-01), Anousis et al.
patent: 6150380 (2000-11-01), Lovqvist et al.
patent: 6166213 (2000-12-01), Anousis et al.
patent: 6191148 (2001-02-01), Anousis et al.
patent: 6328994 (2001-12-01), Shimizu
patent: 6369085 (2002-04-01), Cotton et al.
patent: 6428810 (2002-08-01), Bergstrand et al.
patent: 6462058 (2002-10-01), Fujishima et al.
patent: 6489346 (2002-12-01), Phillips
patent: 6645988 (2003-11-01), Phillips
patent: 6664276 (2003-12-01), Fujishima et al.
patent: 6699885 (2004-03-01), Phillips
patent: 6749864 (2004-06-01), Makino
patent: 6780881 (2004-08-01), Linder
patent: 6780882 (2004-08-01), Phillips
patent: 6818200 (2004-11-01), Foster
patent: 6875872 (2005-04-01), Lindberg et al.
patent: 6939971 (2005-09-01), Fujishima et al.
patent: 7285668 (2007-10-01), Hashimoto et al.
patent: 7351723 (2008-04-01), Linder et al.
patent: 7396841 (2008-07-01), Doen et al.
patent: 7399485 (2008-07-01), Shimizu et al.
patent: 7399772 (2008-07-01), Phillips
patent: 7411070 (2008-08-01), Cotton et al.
patent: 7431942 (2008-10-01), Shimizu et al.
patent: 2002/0013372 (2002-01-01), Ekins
patent: 2002/0094995 (2002-07-01), Foster
patent: 2004/0253180 (2004-12-01), Foster et al.
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0281894 (2007-12-01), Gant et al.
patent: 2008/0033011 (2008-02-01), Tung
patent: 2008/0146610 (2008-06-01), Kohl et al.
patent: 2008/0255200 (2008-10-01), Gant et al.
patent: 2008/0261983 (2008-10-01), Persichetti et al.
patent: 0005129 (1979-10-01), None
patent: WO 9526325 (1995-10-01), None
patent: WO-2007-012650 (2007-02-01), None
patent: WO-2007-012651 (2007-02-01), None
patent: WO 2007023135 (2007-03-01), None
patent: WO 2007039464 (2007-04-01), None
patent: WO 2007041630 (2007-04-01), None
patent: WO 2007143507 (2007-12-01), None
patent: WO 2008035195 (2008-03-01), None
patent: WO 2008114123 (2008-09-01), None
patent: WO 2008127640 (2008-10-01), None
patent: WO 2008130863 (2008-10-01), None
patent: WO 2008131259 (2008-10-01), None
Balant et al., “Metabolic Consdierations, etc.,” Burger's Medicinal Chemistry, 5 ed, 1, Wollf ed. NY: John Wiley & Sons, 1995, 949-982.
Vippagunta et al., “Crystalline Solid”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Guillory (in Brittain ed.), “Polymorphism, etc.,” NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
Tonini et al., “Novel therapeutic strategies in acid-related disorders,” Exp. Op. Ther. Patents 13(5):639-649 (2003).
Crowe, A. M.; The Preparation of Carbon-14-, Sulfur-35-, and Carbon-13-Labeled Forms of Omeprazole. Journal of Labelled Compounds and Radiopharmaceuticals (1986), 23(1), 21-33; Smith Kline and French Res. Ltd., The Frythe/Welwyn/Hertfordshire, UK.
Kushner, D. J et al.; Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds, Canadian Journal of Physiology and Pharmacology (1999), 77(2), 79-88; Department of Botany, University of Toronto, Toronto, ON, Can.
Gant, Thomas G. et al; Substituted Benzimidazoles; not yet published; U.S. Appl. No. 11/818,970, filed Apr. 11, 2007.
Gant, Thomas G. et al; Substituted Benzimidazoles; not yet published; U.S. Appl. No. 12/082,470, filed Apr. 11, 2008.
Wang, Haiyong et al.; Preparation of 8-Deuterium-substituted Omeprazole Sodium in situ; Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 10085.
TLC PharmaChem; Omeprazole-d3; CAS No. 73590-58-6; TLC ID/catalog No: O-021; website: http://www. tlcpharmachem.com/tlc/tlc—item.php?upc=O-021&li=le—21&sub=A.
Bauer, LA; et al.; Influence of long-term infusions on lidocaine kinetics; Clin. Pharmacol. Ther. 31(4), 433-437 (1982).
Drug Report for Omeprazole, Thomson Investigational Drug Database; downloaded Jan. 25, 2009.
Borgstrom, L et al; Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect; J Pharm Sci, 77(11) 952-4 (1988).
Browne, TR; Chapter 2. Isotope Effect: Implications for pharmaceutical investigations; Stable isotopes in pharmaceutical research; Elsevier; Amsterdam, 1997.
Browne, TR et al.; Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man; J Clin Pharmacol, 22, 309-15 (1982).
Burn, AGL et al.; Pharmacokinetics of Lidocaine and Bupivacaine and stbel isotope labelled analogues: a study in healthy volunteers; Biopharma & Drug Disp, 9 85-95 (1988).
Elison, C. et al.; Effect of deuteration of N-CH3 Group on Potency and enzymatic N-demethylation of morphine; Science, 134(3485) 1078-9 (1961).
Farmer, PB et al.; Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexy1-1-nitrosourea; J Med Chem, 21(6) 514-520 (1978).
Fisher, MB et al.; The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism; Curr Opin in Drug Disc & Develop 9(1) 101-109 (2006).
Foster, AB; Deuterium isotope effects in studies of drug metabolism; Trends in Pharma Sci, 524-527 (1984).
Helfenbein, J et al; Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic; J Med Chem, 45, 5806-5808 (2002).
Lee, H. et al; Deuterium magic angle spinning studies of substrates bound to cytochrome P450; Biochem. 38 10808-13 (1999).
Mamada, K. et al.; Pharmacokinetic equivalence of deuterium-labeled and unlabeled phenytoin; Drug Metab Disp. 14 (4) 509-11 (1986).
Nelson, SD. et al.; The use of deuterium isotope effects to probe the active site properties, mechanism, of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity; Drug Metab Disp. 31(12) 1481-98 (2003).
Nelson, SD et al.; Primary and B-Secondary Deuterium Isotope Effects in N-Deethylation reactions; J Med Chem. 18(11) 1062-1065 (1975).
Pohl, LR et al.; Determination of Toxic Pathways of Metabolism by Deuterium Substitution; Drug Metab Rev. 15(7) 1335-51 (1984-5).
Rampe, D. et al.; Deuterated analogs of Verapamil and Nifedipine. Synthesis and biological activity; Eur J Med Chem. 28 259-263 (1993).
Medical Isotopes, Inc.; Lansoprazole-d4, catalog No. D11327 website: http://www.medicalisotopes.com/Product—Details.asp?find=26952.
TLC PharmaChem; Pantoprazole-d3; CAS No. 102625-70-7 TLC ID# (catalog No.): P-013 website: http://www.tlcpharmachem.com/tlc/tlc—item.php?upc=P-013&li=le—21&sub=P.
Gant Thomas G.
Sarshar Sepehr
Auspex Pharmaceuticals, Inc
Bennett Dennis A.
Morris Patricia L
Sertic Michael
LandOfFree
Inhibitors of the gastric H + , K + -ATPase with enhanced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the gastric H + , K + -ATPase with enhanced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the gastric H + , K + -ATPase with enhanced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4089725